Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery ...

Regulatory reviews for ribociclib among patients with early breast cancer are continuously ongoing to include the EMA and China. 1. FDA approves Kisqali with an aromatase inhibitor and Kisqali Femara ...

The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It ...

Kisqali has been FDA-approved with an aromatase inhibitor as postsurgical treatment for some with early breast cancer at a ...

The drug joins abemaciclib (Verzenio) as approved CDK4/6 inhibitors in this setting, but the broader indication for ...

Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA on Tuesday approved ribociclib (Kisqali) in ...

This new indication also applies to Kisqali Femara Co-Pack (ribociclib with letrozole). The approval was based on data from the phase 3 NATALEE trial (NCT03701334), which enrolled 5101 adults with ...